IVI in the Media

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

EuBiologics Acquires Licensure for New Cholera Vaccine

Author
Master
Date
2015-02-17 00:00
Views
4257

EuBiologics Acquires Licensure for New Cholera Vaccine
- First cholera vaccine made in Korea for use in developing world
- Global health partnership between EuBiologics and International Vaccine Institute to control cholera in poor countries
- Application for WHO approval underway


 

Seoul, South Korea - EuBiologics Co., Ltd. and the International Vaccine Institute (IVI) announced that the inactivated oral cholera vaccine (OCV) Euvichol obtained licensure for export from the South Korean Ministry of Food and Drug Safety on January 28, 2015, making this the first cholera vaccine produced in Korea and paving the way for vaccine approval by the World Health Organization (WHO). An application has already been submitted for obtaining WHO prequalification of Euvichol.


 

“After several years of hard work and effort, we are extremely pleased that Euvichol has been licensed since we are one step closer to WHO prequalification and ensuring access of the vaccine for the world’s poor,” said Mr. Yeong-Ok Baik, EuBiologics CEO, “We are thankful to IVI for their support in helping make this happen.”


 

Since 2010, EuBiologics and IVI have been collaborating on the development and production of a new inactivated oral cholera vaccine following technology transfer from IVI to EuBiologics. Their aim is to ensure a reliable global supply of safe, effective and affordable cholera vaccines to prevent and control endemic and epidemic cholera in the world’s poorest communities. Cholera is a potentially fatal infectious disease that causes acute watery diarrhea. It is a disease of poverty and strikes in areas with poor sanitation and lack of clean water. Approximately 3 million people are infected and up to 100,000 people die from cholera annually, the majority of which are from developing countries in Africa and South Asia.


 

In collaboration with partners in Vietnam, Sweden, the United States and South Korea, IVI reformulated the oral inactivated cholera vaccine and transferred the technology to Shantha Biotechnics (part of the Sanofi group), an Indian manufacturer. The vaccine Shanchol was licensed in India in 2009 and WHO-prequalified in 2011. In 2010, IVI transferred technology for the cholera vaccine to EuBiologics, which was unprecedented for a Korean company at the time. Euvichol will be the third internationally licensed vaccine against cholera (Shanchol and Dukoral produced by Crucell, part of Johnson & Johnson).


 

The development of Euvichol started with preclinical studies that included production of consistency lots at the EuBiologics cGMP (current Good Manufacturing Practice) facility in Chuncheon and toxicology studies to establish safety prior to human studies. The clinical studies were conducted beginning with a phase I study in Korea to establish safety in a small number of people and to demonstrate an immune response against cholera. Following the success of the phase I trial, a phase III trial was conducted in about 3,600 people in the Philippines, which established that Euvichol was safe and highly immunogenic.


 

IVI has been providing support to EuBiologics in production, quality control and clinical vaccine evaluation. In addition, IVI has been providing advice to EuBiologics on the conduct of the clinical trials and application for WHO prequalification. EuBiologics has also received excellent support from the Korean Ministry of Food and Drug Safety through its “consultative groups” for supporting global vaccine commercialization and WHO-PQ accreditation. The Ministry has provided advice on licensure of the vaccine including GMP issues and clinical development.


 

EuBiologics intends to license Euvichol in cholera-endemic countries or where there is potential for cholera outbreaks such as Dominican Republic, Haiti, Pakistan, the Philippines, Thailand, and Egypt. It is anticipated that sales of Euvichol will begin in the first half of this year. WHO prequalification is expected to be obtained in early 2016, which will in turn open the door to internationalization of the vaccine through sales to international organizations such as UNICEF and Gavi, the Vaccine Alliance. Euvichol will be the first WHO-prequalified cholera vaccine from Korea, highlighting the contribution Korea is making to public health through its vaccine initiatives.


 

“Euvichol will be an important advance for the control of cholera, a deadly diarrheal disease that sickens and kills countless people in the developing world,” said Dr. Jerome H. Kim, IVI’s Director General Elect, “Thanks to our partnership with EuBiologics and to the support of Korea, we can save more lives and improve the health and wellbeing of the poorest people in the world.”



 

About PQ(Pre-qualification)
WHO prequalification indicates that the vaccine meets international standards in quality, safety and efficacy, and enables the vaccine to be purchased by UN agencies.


 

About IVI
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.


 

About EuBiologics
EuBiologics Co., Ltd. is a biopharmaceutical company conducting development and commercialization for safe and effective vaccines to improve the public health in developing countries and supplying a wide range of “Contract Research and Manufacturing Organization” (CRMO) services for the development of biologics. Since EuBiologics was established in March 2010 it has been working on the commercialization of OCV with the assistance of IVI and developing bacterial or viral vaccines for supplying safe and effective vaccines to the public sector. EuBiologics is capable of manufacturing a variety of mammalian cell and microbe-derived, protein-based therapeutics and antibodies. It provides customized services for various stages of product development, including cell line development, GMP production, validation and regulatory support. To learn more about EuBiologics, please visit http://www.eubiologics.com.


 

Media Contact:


 

IVI
Tae Kyung Byun
Public Awareness/Advocacy Officer, IVI
Phone: +82-2-872-2801 (Ext. 159)
Mobile: +82-11-9773-6071
Email: tkbyun@ivi.int


 

Burson-Marsteller Korea
Ayoung Jang Nayoung Kim
Phone: +82-2-3782-6465 +82-2-3782-6458
Mobile: +82-10-3596-2440 +82-10-8967-1909
Email: Ayoung.Jang@bm.com Nayoung.Kim@bm.com


 

EuBiologics
Dr. Sue-nie Park
Vice President
EuBiologics Co., Ltd.
Phone: +82-02-572-6675
Mobile: +82-10-4115-4093
Email: suenie@eubiologics.com

DONATE